Gut microbiome influences efficacy of PD-1based immunotherapy against epithelial tumors

This piece of research is behind the headline: Gut bacteria " boost " cancer therapy. This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies).The findings are of interest, but don't have any immediate implications for cancer treatment.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news

Related Links:

UCLA researchers have discovered  genetic similarities between the adult stem cells responsible for maintaining and repairing epithelial tissues — which line all of the organs and cavities inside the body — and the cells that drive aggressive epithelial cancers. Their findings could bring about a better understanding of how ag gressive, treatment-resistant cancers develop and progress, and could eventually lead to new drugs for a range of advanced epithelial cancers such as lung, prostate and bladder cancers. The study, led by senior authors Owen Witte and Thomas Graeber, both of the  UCLA E...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
AbstractBackgroundThe clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor types, including lung cancer. However, the immunological profile of non –small cell lung carcinoma (NSCLC) treated with neoadjuvant chemotherapy (NCT) is not yet fully characterized, and it may be therapeutically important. The aim of this retrospective study was to characterize and quantify PD-L1/PD-1 expression and tumor-associated immune cells (TAICs) in surgically resected NSCLCs from patien...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
In conclusion, EM-L2 displaying phage particles could be deemed as an encouraging strategy in contemporary cancer immunotherapy. PMID: 29908541 [PubMed - in process]
Source: Iranian Journal of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Iran J Allergy Asthma Immunol Source Type: research
Routy B, Le Chatelier E, Derosa L, et  al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2017 Nov 2. pii: eaan3706. https://doi.org/10.1126/science.aan3706.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Selected Summaries Source Type: research
Sarah Shigdar The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not shown as much promise as initially...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
David Grimm —online news editor for Science—talks with Sarah Crespi about a long-term project monitoring raccoon latrines in California. What influence do these wild bathrooms have on the ecosystem? Sarah also interviews Christian Jobin of the University of Florida in Gainesville about his Perspective on t hree papers linking the success of cancer immunotherapy with microbes in the gut—it turns out which bacteria live in a cancer patient’s intestines can predict their response to this cutting edge cancer treatment. Read the related papers: Routy et al., Gut microbiome influences efficacy of ...
Source: Science Magazine Podcast - Category: Science Authors: Tags: Scientific Community Source Type: podcasts
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Source Type: news
Authors: Campesato LF, Silva APM, Cordeiro L, Correa BR, Navarro FCP, Zanin RF, Marçola M, Inoue LT, Duarte ML, Molgora M, Pasqualini F, Massara M, Galante P, Barroso-Sousa R, Polentarutti N, Riva F, Costa ET, Mantovani A, Garlanda C, Camargo AA Abstract Tumors develop numerous strategies to fine-tune inflammation and avoid detection and eradication by the immune system. The identification of mechanisms leading to local immune dysregulation is critical to improve cancer therapy. We here demonstrate that Interleukin-1 receptor 8 (IL-1R8 - previously known as SIGIRR/TIR8), a negative regulator of Toll-Like and...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Metastatic cancers are the cause of up to 90% of cancer deaths, yet few treatment options exist for patients with metastatic disease. Adoptive transfer of T cells that express tumor-reactive T-cell receptors (TCRs) has been shown to mediate regression of metastatic cancers in some patients. Unfortunately, identification of antigens that are expressed solely by cancer cells and not normal tissues has been a major challenge for the development of T-cell based immunotherapies. Thus, it is essential to find novel target antigens that are differentially expressed in cancer versus normal tissues.Researchers at the National Cance...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
This study included 647 patients 80 to 106 years of age who had audiometric evaluations at an academic medical center (141 had multiple audiograms). The degree of hearing loss was compared across the following age brackets: 80 to 84 years, 85 to 89 years, 90 to 94 years, and 95 years and older. From an individual perspective, the rate of hearing decrease between 2 audiograms was compared with age. The researchers found that changes in hearing among age brackets were higher during the 10th decade of life than the 9th decade at all frequencies for all the patients (average age, 90 years). Correspondingly, the annual rate of ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Cancer | Cancer & Oncology | Cancer Therapy | Epithelial Cancer | Health | Immunotherapy | Study